Daratumumab and hyaluronidase
| Daratumumab and hyaluronidase | |
|---|---|
| Term | Daratumumab and hyaluronidase |
| Short definition | Daratumumab and hyaluronidase - (pronounced) (DAYR-uh-TOOM-yoo-mab. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Daratumumab and hyaluronidase - (pronounced) (DAYR-uh-TOOM-yoo-mab. . . HY-al-yoo-RAH-nih-days) combination of two medicines used alone or with other medicines to treat adults with certain types of multiple myeloma or light chain amyloidosis. It is also being studied in the treatment of other types of cancer. Daratumumab attaches to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab can block CD38 and help the immune system kill cancer cells. Hyaluronidase allows daratumumab to be injected under the skin. Daratumumab and hyaluronidase can be administered in less time than daratumumab alone, which is given as an infusion. Also called Darzalex Faspro
External links
- Medical encyclopedia article on Daratumumab and hyaluronidase
- Wikipedia's article - Daratumumab and hyaluronidase
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski